Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Pesini

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Revolutionizing Alzheimer's disease and clinical trials through biomarkersNiklas Mattsson, Maria C Carrillo, Robert A Dean, et al.
Alzheimer'S Research & Therapy|October 23, 2021
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohortHyemin Jang, Ji Sun Kim, Hye Joo Lee, et al.
Brain Communications|September 21, 2020
Longitudinal evaluation of the natural history of amyloid-β in plasma and brainSamantha C Burnham, Noelia Fandos, Christopher Fowler, et al.
Nature Aging|April 28, 2023
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinationsNicholas C Cullen, Antoine Leuzy, Sebastian Palmqvist, et al.
Alzheimer'S Research & Therapy|December 9, 2014
Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volumeOscar Sotolongo-Grau, Pedro Pesini, Sergi Valero, et al.
Plos One|December 7, 2013
Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariatesAgustín Ruiz, Pedro Pesini, Ana Espinosa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 21, 2021
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tauShorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, et al.
Alzheimer'S Research & Therapy|December 3, 2019
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 StudyVirginia Pérez-Grijalba, Javier Arbizu, Judith Romero, et al.
Alzheimer'S Research & Therapy|January 31, 2018
Safety, tolerability and immunogenicity of an active anti-Aβ<sub>40</sub> vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trialAna-María Lacosta, María Pascual-Lucas, Pedro Pesini, et al.
Frontiers in Aging Neuroscience|December 15, 2018
Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest OldGorka Fernández-Eulate, Ainhoa Alberro, Maider Muñoz-Culla, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Revolutionizing Alzheimer's disease and clinical trials through biomarkersNiklas Mattsson, Maria C Carrillo, Robert A Dean, et al.
Alzheimer'S Research & Therapy|October 23, 2021
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohortHyemin Jang, Ji Sun Kim, Hye Joo Lee, et al.
Brain Communications|September 21, 2020
Longitudinal evaluation of the natural history of amyloid-β in plasma and brainSamantha C Burnham, Noelia Fandos, Christopher Fowler, et al.
Nature Aging|April 28, 2023
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinationsNicholas C Cullen, Antoine Leuzy, Sebastian Palmqvist, et al.
Alzheimer'S Research & Therapy|December 9, 2014
Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volumeOscar Sotolongo-Grau, Pedro Pesini, Sergi Valero, et al.
Plos One|December 7, 2013
Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariatesAgustín Ruiz, Pedro Pesini, Ana Espinosa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 21, 2021
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tauShorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, et al.
Alzheimer'S Research & Therapy|December 3, 2019
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 StudyVirginia Pérez-Grijalba, Javier Arbizu, Judith Romero, et al.
Alzheimer'S Research & Therapy|January 31, 2018
Safety, tolerability and immunogenicity of an active anti-Aβ<sub>40</sub> vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trialAna-María Lacosta, María Pascual-Lucas, Pedro Pesini, et al.
Frontiers in Aging Neuroscience|December 15, 2018
Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest OldGorka Fernández-Eulate, Ainhoa Alberro, Maider Muñoz-Culla, et al.
Pageof 4